Qurse Revand for MASLD: A Randomized Controlled Safety and Efficacy Trial

Inclusion criteria: * Diagnosed Cases of Fatty Liver (Grade Ⅰ \&Ⅱ) by USG. * Participants with Presence of at least 1or more cardiometabolic risk factor 1. Excess adiposity (BMI of ≥25 kg/m², Waist circumference of ≥94 cm in men and ≥80 cm in women) 2. Disorders of glucose metabolism (Prediabetes- HbA1c (5.7% to 6.4 %), FPG- 100 to 125 mg/dL, Type 2 diabetes mellitus- HbA1c of ≥6.5%; FPG of ≥126 mg/dL) 3. Hypertriglyceridemia (Plasma triglycerides ≥150 mg/dL) 4. High-density lipoprotein (HDL) cholesterol: \<40 mg/dL in men or ≤50 mg/dL in women 5. Arterial hypertension: Resting blood pressure of 130/85 mm Hg or greater or ongoing antihypertensive treatment * Participants with minimal or no alcohol intake (i.e. \<20 g/day for females and \<30 g/day for males). * Participants of any gender, aged between 20-60yrs. Exclusion criteria: * Pregnant And Lactating Mother * Fatty Liver Grade Ⅲ (by USG) * Known History of Hepatitis, Liver Cancer, systemic disorders like Malignancies, cardiovascular diseases. * Participants on medications causing steatosis (Amiodarone, Valproic Acid, Methotrexate, Tamoxifen, Glucocorticoids)